Bernstein analyst Florent Cespedes maintained a Hold rating on Merck KGaA (0O14 – Research Report) today and set a price target of €168.00. The ...

With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 ...

Merck KGaA has developed a vision of a SMARTfacturing ecosystem. [Merck KGaA/Darmstadt, Germany] Merck KGaA has developed a SMARTfacturing vision ecosystem, which is a structured, multi-layered ...

Merck KGaA, Darmstadt, Germany, and Zebra Technologies Corporation have announced a collaboration to develop solutions for ...

Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestments have strengthened its position in these ...

This article is an update to previous coverage on Merck. In 2024, the German company reported a total revenue of 21.2B EUR, an increase of approximately 1% compared to 2023. The gross margin ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption rates ...

Zebra Technologies Corporation (NASDAQ: ZBRA), a global leader in digitising and automating frontline workflows, and Merck ...

Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently signed with ...

Merck KGaA is doubling down on AI through a new collaboration agreement with tech firm Iktos, using its generative modelling technology to speed up the discovery and design of promising new compounds.